KR20220119429A - 감마-히드록시부티레이트(ghb) 투약 - Google Patents

감마-히드록시부티레이트(ghb) 투약 Download PDF

Info

Publication number
KR20220119429A
KR20220119429A KR1020227024876A KR20227024876A KR20220119429A KR 20220119429 A KR20220119429 A KR 20220119429A KR 1020227024876 A KR1020227024876 A KR 1020227024876A KR 20227024876 A KR20227024876 A KR 20227024876A KR 20220119429 A KR20220119429 A KR 20220119429A
Authority
KR
South Korea
Prior art keywords
oxybate
mixed salt
administered
patient
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227024876A
Other languages
English (en)
Korean (ko)
Inventor
프랑크 스코비에란다
Original Assignee
재즈 파마슈티칼즈 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재즈 파마슈티칼즈 아일랜드 리미티드 filed Critical 재즈 파마슈티칼즈 아일랜드 리미티드
Publication of KR20220119429A publication Critical patent/KR20220119429A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
KR1020227024876A 2019-12-24 2020-12-22 감마-히드록시부티레이트(ghb) 투약 Withdrawn KR20220119429A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962953288P 2019-12-24 2019-12-24
US62/953,288 2019-12-24
US202062993372P 2020-03-23 2020-03-23
US62/993,372 2020-03-23
US202063000547P 2020-03-27 2020-03-27
US63/000,547 2020-03-27
US202063052676P 2020-07-16 2020-07-16
US63/052,676 2020-07-16
PCT/US2020/066561 WO2021133778A1 (en) 2019-12-24 2020-12-22 Gamma-hydroxybutyrate (ghb) dosing

Publications (1)

Publication Number Publication Date
KR20220119429A true KR20220119429A (ko) 2022-08-29

Family

ID=74191949

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227024876A Withdrawn KR20220119429A (ko) 2019-12-24 2020-12-22 감마-히드록시부티레이트(ghb) 투약

Country Status (14)

Country Link
US (3) US20210186907A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081204A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023508975A (cg-RX-API-DMAC7.html)
KR (1) KR20220119429A (cg-RX-API-DMAC7.html)
CN (1) CN115209885A (cg-RX-API-DMAC7.html)
AU (1) AU2020414694A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012594A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162974A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001743A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010330A2 (cg-RX-API-DMAC7.html)
IL (1) IL294176A (cg-RX-API-DMAC7.html)
MX (1) MX2022007968A (cg-RX-API-DMAC7.html)
TW (1) TW202135790A (cg-RX-API-DMAC7.html)
WO (1) WO2021133778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391660B (es) 2010-03-24 2025-03-21 Jazz Pharmaceuticals Inc Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US12582622B2 (en) 2020-10-08 2026-03-24 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
AU2001291173A1 (en) 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
EP2566462B1 (en) * 2010-05-04 2020-07-08 Jazz Pharmaceuticals Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders

Also Published As

Publication number Publication date
CN115209885A (zh) 2022-10-18
WO2021133778A1 (en) 2021-07-01
BR112022012594A2 (pt) 2022-09-06
MX2022007968A (es) 2022-09-02
TW202135790A (zh) 2021-10-01
US20240285560A1 (en) 2024-08-29
CA3162974A1 (en) 2021-07-01
AU2020414694A1 (en) 2022-08-18
IL294176A (en) 2022-08-01
US20210186907A1 (en) 2021-06-24
US20210361601A1 (en) 2021-11-25
CO2022010330A2 (es) 2022-10-21
EP4081204A1 (en) 2022-11-02
JP2023508975A (ja) 2023-03-06
CL2022001743A1 (es) 2023-02-10

Similar Documents

Publication Publication Date Title
US20240285560A1 (en) Ghb dosing
US11426373B2 (en) Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
JP2023515472A (ja) 特発性過眠症の治療法
US11219611B2 (en) Formulations of L-ornithine phenylacetate
US11911382B2 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension
US20130172414A1 (en) Pharmaceutical composition comprising levocarnitine and dobesilate
US20240024316A1 (en) Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
AU2016353350A1 (en) Formulation of L-ornithine phenylacetate
US8053472B2 (en) Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus
JP7344422B2 (ja) 糖尿病予防・治療用の医薬品組成物及びその用途
US20250161270A1 (en) Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor
HK40065546A (en) A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing
WO2017217072A1 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20250107

WITB Written withdrawal of application